GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Equity-to-Asset

Chiome Bioscience (TSE:4583) Equity-to-Asset : 0.71 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Chiome Bioscience's Total Stockholders Equity for the quarter that ended in Mar. 2024 was 円1,247.6 Mil. Chiome Bioscience's Total Assets for the quarter that ended in Mar. 2024 was 円1,753.9 Mil. Therefore, Chiome Bioscience's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.71.

The historical rank and industry rank for Chiome Bioscience's Equity-to-Asset or its related term are showing as below:

TSE:4583' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.66   Med: 0.93   Max: 0.96
Current: 0.71

During the past 13 years, the highest Equity to Asset Ratio of Chiome Bioscience was 0.96. The lowest was 0.66. And the median was 0.93.

TSE:4583's Equity-to-Asset is ranked better than
54.69% of 1558 companies
in the Biotechnology industry
Industry Median: 0.67 vs TSE:4583: 0.71

Chiome Bioscience Equity-to-Asset Historical Data

The historical data trend for Chiome Bioscience's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Equity-to-Asset Chart

Chiome Bioscience Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.93 0.89 0.81 0.81 0.66

Chiome Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.68 0.69 0.66 0.71

Competitive Comparison of Chiome Bioscience's Equity-to-Asset

For the Biotechnology subindustry, Chiome Bioscience's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiome Bioscience's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's Equity-to-Asset falls into.



Chiome Bioscience Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Chiome Bioscience's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1157.723/1751.454
=0.66

Chiome Bioscience's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=1247.567/1753.934
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chiome Bioscience  (TSE:4583) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Chiome Bioscience Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Chiome Bioscience (TSE:4583) Business Description

Traded in Other Exchanges
N/A
Address
Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience (TSE:4583) Headlines

No Headlines